The antibiotic effect of silver CAPD catheter on peritoneal dialysis-related infections : a multicenter randomized open-label trial (ASCA-PD study)

未提供0 个研究点目标入组 250 人开始时间: 2025年5月16日最近更新: 2025年6月13日

适应症

试验速览

暂无简介。

•Patients requiring reintroduction after kidney transplantation or hemodialysis
•Emergency peritoneal dialysis initiation patients
•Cases involving the creation of an exit site in special locations with extended catheters (excluding upper abdominal exit sites)
•Patients with a history of metal allergies, including sensitivity to silver.
•Patients with a prognosis of less than one year at the time of initiation (e.g., terminal cancer patients)
•Patients with a history of Severe liver cirrhosis (Child-Pugh grade C)
•Complications with skin conditions such as common infections or atopic dermatitis
•Patients with gastrostomy or colostomy
•Use of immunosuppressants (including oral and/or intravenous corticosteroids administration)

All exit-site and tunnel infections (composite endpoint)

时间窗: 12 months after exit-site formation (peritoneal dialysis initiation)

All exit-site and tunnel infections (composite endpoint)

All exit-site and tunnel infections within 12 months(12 months after exit-site creation)
First occurrence of exit-site and tunnel infections within 12 months(12 months after exit-site creation)
First occurrence of exit-site and tunnel infections with competing risks(12 months after exit-site creation)
Exit-site and tunnel infections within 30 days(30 days after exit-site creation)
All cases of peritonitis after catheter insertion
Catheter removal after insertion
Catheter removal due to infection or complications(30 days after catheter insertion)
Catheter patency
Allergic reactions after catheter insertion
Refractory or recurrent infections
Colony formation and culture results(12 months after exit-site creation or at catheter removal within 12 months)
Technique failure
Transition to hybrid therapy

发起方

未提供